Skip to content
HowShorted

Apellis Pharmaceuticals, Inc. short interest in 2021

In 2021, Apellis Pharmaceuticals, Inc.'s disclosed short interest ran from 11.81% of shares outstanding on 15 Jan 2021 to 7.66% on 31 Dec 2021, a change of -4.15 percentage points. The year's high was 11.81% on 15 Jan 2021 and its low 5.81% on 13 Aug 2021, averaging 8.17% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 18.65 days on 26 Feb 2021. Full history: Apellis Pharmaceuticals, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Apellis Pharmaceuticals, Inc. in 2021

2021 in figures

Start of year
11.81% (15 Jan 2021)
End of year
7.66% (31 Dec 2021)
Change
-4.15 pp
High
11.81% (15 Jan 2021)
Low
5.81% (13 Aug 2021)
Average
8.17%
Highest days to cover
18.65 (26 Feb 2021)
SEC filings marked
4

Every report in 2021

Apellis Pharmaceuticals, Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 202111.81%15.65
29 Jan 202110.11%11.04
12 Feb 202110.23%14.98
26 Feb 202110.71%18.6510-K filed
15 Mar 20219.29%13.54
31 Mar 202110.15%10.56
15 Apr 202110.62%14.13
30 Apr 20219.59%13.5710-Q filed
14 May 20218.57%12.10
28 May 20216.97%4.20
15 Jun 20217.42%10.08
30 Jun 20217.38%7.86
15 Jul 20217.74%5.69
30 Jul 20216.10%6.17
13 Aug 20215.81%6.1710-Q filed
31 Aug 20215.94%5.64
15 Sep 20216.57%1.18
30 Sep 20217.33%4.07
15 Oct 20216.58%6.48
29 Oct 20216.84%7.43
15 Nov 20216.75%4.0210-Q filed
30 Nov 20217.58%4.05
15 Dec 20218.27%8.63
31 Dec 20217.66%9.06

See also: Apellis Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.